Antiphospholipid-thrombosis syndromes

Rodger L. Bick, Banu Arun, Eugene P. Frenkel

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Antiphospholipid antibodies are strongly associated with thrombosis and appear to be the most common of the acquired blood protein defects causing thrombosis. Based upon our experience, ~25% of patients with unexplained venous thrombosis, ~60% of patients with cerebrovascular thrombosis, ~37% of patients with transient ischemic attacks, ~18% with premature coronary artery thrombosis and ~60% of patients with recurrent fetal loss (recurrent miscarriage syndrome) harbor antiphospholipid antibodies. Although the precise mechanism(s) whereby antiphospholipid antibodies alter hemostasis to induce a hypercoagulable state remain unclear, several theories have been advanced. Since the aPTT is unreliable in patients with lupus anticoagulant and is not usually prolonged in patients with anticardiolipin antibodies, definitive tests, ELISA for IgG, IgA and IgM anticardiolipin antibodies and the dilute Russel's viper venom time (followed by cephalin correction for confirmation) for lupus anticoagulant should be immediately ordered when suspecting the antiphospholipid syndrome in individuals with otherwise unexplained thrombotic or thromboembolic events or recurrent fetal loss. However, if one strongly suspects antiphospholipid thrombosis syndrome clinically and assays for lupus anticoagulants and anticardiolipin antibodies are negative, specific assays for all three idiotypes of phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, phosphatidylinositol and phosphatidylglycerol are available and should be considered. These may clearly be indicated for difficult diagnostic cases of fetal wastage syndrome, and cerebrovascular events, but their significance in other types of thrombosis, particularly venous, remains unclear at present. Since about 65% of patients with antiphospholipid antibodies will fail warfarin therapy (rethrombose), it is important to define this common defect and institute appropriate antithrombotic therapy for appropriate time periods.

Original languageEnglish (US)
Pages (from-to)100-110
Number of pages11
JournalHaemostasis
Volume29
Issue number2-3
StatePublished - Dec 1999

Fingerprint

Antiphospholipid Syndrome
Thrombosis
Lupus Coagulation Inhibitor
Anticardiolipin Antibodies
Antiphospholipid Antibodies
Venous Thrombosis
Viper Venoms
Phosphatidylethanolamines
Coronary Thrombosis
Habitual Abortion
Phosphatidylglycerols
Phosphatidylserines
Transient Ischemic Attack
Warfarin
Phosphatidylinositols
Hemostasis
Phosphatidylcholines
Immunoglobulin A
Immunoglobulin M
Blood Proteins

Keywords

  • Anticardiolipin antibody
  • Lupus anticoagulant
  • Miscarriage
  • Premature stroke
  • Thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Bick, R. L., Arun, B., & Frenkel, E. P. (1999). Antiphospholipid-thrombosis syndromes. Haemostasis, 29(2-3), 100-110.

Antiphospholipid-thrombosis syndromes. / Bick, Rodger L.; Arun, Banu; Frenkel, Eugene P.

In: Haemostasis, Vol. 29, No. 2-3, 12.1999, p. 100-110.

Research output: Contribution to journalArticle

Bick, RL, Arun, B & Frenkel, EP 1999, 'Antiphospholipid-thrombosis syndromes', Haemostasis, vol. 29, no. 2-3, pp. 100-110.
Bick RL, Arun B, Frenkel EP. Antiphospholipid-thrombosis syndromes. Haemostasis. 1999 Dec;29(2-3):100-110.
Bick, Rodger L. ; Arun, Banu ; Frenkel, Eugene P. / Antiphospholipid-thrombosis syndromes. In: Haemostasis. 1999 ; Vol. 29, No. 2-3. pp. 100-110.
@article{801f5767e9f642c5be03e8b1707abf1a,
title = "Antiphospholipid-thrombosis syndromes",
abstract = "Antiphospholipid antibodies are strongly associated with thrombosis and appear to be the most common of the acquired blood protein defects causing thrombosis. Based upon our experience, ~25{\%} of patients with unexplained venous thrombosis, ~60{\%} of patients with cerebrovascular thrombosis, ~37{\%} of patients with transient ischemic attacks, ~18{\%} with premature coronary artery thrombosis and ~60{\%} of patients with recurrent fetal loss (recurrent miscarriage syndrome) harbor antiphospholipid antibodies. Although the precise mechanism(s) whereby antiphospholipid antibodies alter hemostasis to induce a hypercoagulable state remain unclear, several theories have been advanced. Since the aPTT is unreliable in patients with lupus anticoagulant and is not usually prolonged in patients with anticardiolipin antibodies, definitive tests, ELISA for IgG, IgA and IgM anticardiolipin antibodies and the dilute Russel's viper venom time (followed by cephalin correction for confirmation) for lupus anticoagulant should be immediately ordered when suspecting the antiphospholipid syndrome in individuals with otherwise unexplained thrombotic or thromboembolic events or recurrent fetal loss. However, if one strongly suspects antiphospholipid thrombosis syndrome clinically and assays for lupus anticoagulants and anticardiolipin antibodies are negative, specific assays for all three idiotypes of phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, phosphatidylinositol and phosphatidylglycerol are available and should be considered. These may clearly be indicated for difficult diagnostic cases of fetal wastage syndrome, and cerebrovascular events, but their significance in other types of thrombosis, particularly venous, remains unclear at present. Since about 65{\%} of patients with antiphospholipid antibodies will fail warfarin therapy (rethrombose), it is important to define this common defect and institute appropriate antithrombotic therapy for appropriate time periods.",
keywords = "Anticardiolipin antibody, Lupus anticoagulant, Miscarriage, Premature stroke, Thrombosis",
author = "Bick, {Rodger L.} and Banu Arun and Frenkel, {Eugene P.}",
year = "1999",
month = "12",
language = "English (US)",
volume = "29",
pages = "100--110",
journal = "Haemostasis",
issn = "0301-0147",
publisher = "S. Karger AG",
number = "2-3",

}

TY - JOUR

T1 - Antiphospholipid-thrombosis syndromes

AU - Bick, Rodger L.

AU - Arun, Banu

AU - Frenkel, Eugene P.

PY - 1999/12

Y1 - 1999/12

N2 - Antiphospholipid antibodies are strongly associated with thrombosis and appear to be the most common of the acquired blood protein defects causing thrombosis. Based upon our experience, ~25% of patients with unexplained venous thrombosis, ~60% of patients with cerebrovascular thrombosis, ~37% of patients with transient ischemic attacks, ~18% with premature coronary artery thrombosis and ~60% of patients with recurrent fetal loss (recurrent miscarriage syndrome) harbor antiphospholipid antibodies. Although the precise mechanism(s) whereby antiphospholipid antibodies alter hemostasis to induce a hypercoagulable state remain unclear, several theories have been advanced. Since the aPTT is unreliable in patients with lupus anticoagulant and is not usually prolonged in patients with anticardiolipin antibodies, definitive tests, ELISA for IgG, IgA and IgM anticardiolipin antibodies and the dilute Russel's viper venom time (followed by cephalin correction for confirmation) for lupus anticoagulant should be immediately ordered when suspecting the antiphospholipid syndrome in individuals with otherwise unexplained thrombotic or thromboembolic events or recurrent fetal loss. However, if one strongly suspects antiphospholipid thrombosis syndrome clinically and assays for lupus anticoagulants and anticardiolipin antibodies are negative, specific assays for all three idiotypes of phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, phosphatidylinositol and phosphatidylglycerol are available and should be considered. These may clearly be indicated for difficult diagnostic cases of fetal wastage syndrome, and cerebrovascular events, but their significance in other types of thrombosis, particularly venous, remains unclear at present. Since about 65% of patients with antiphospholipid antibodies will fail warfarin therapy (rethrombose), it is important to define this common defect and institute appropriate antithrombotic therapy for appropriate time periods.

AB - Antiphospholipid antibodies are strongly associated with thrombosis and appear to be the most common of the acquired blood protein defects causing thrombosis. Based upon our experience, ~25% of patients with unexplained venous thrombosis, ~60% of patients with cerebrovascular thrombosis, ~37% of patients with transient ischemic attacks, ~18% with premature coronary artery thrombosis and ~60% of patients with recurrent fetal loss (recurrent miscarriage syndrome) harbor antiphospholipid antibodies. Although the precise mechanism(s) whereby antiphospholipid antibodies alter hemostasis to induce a hypercoagulable state remain unclear, several theories have been advanced. Since the aPTT is unreliable in patients with lupus anticoagulant and is not usually prolonged in patients with anticardiolipin antibodies, definitive tests, ELISA for IgG, IgA and IgM anticardiolipin antibodies and the dilute Russel's viper venom time (followed by cephalin correction for confirmation) for lupus anticoagulant should be immediately ordered when suspecting the antiphospholipid syndrome in individuals with otherwise unexplained thrombotic or thromboembolic events or recurrent fetal loss. However, if one strongly suspects antiphospholipid thrombosis syndrome clinically and assays for lupus anticoagulants and anticardiolipin antibodies are negative, specific assays for all three idiotypes of phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, phosphatidylinositol and phosphatidylglycerol are available and should be considered. These may clearly be indicated for difficult diagnostic cases of fetal wastage syndrome, and cerebrovascular events, but their significance in other types of thrombosis, particularly venous, remains unclear at present. Since about 65% of patients with antiphospholipid antibodies will fail warfarin therapy (rethrombose), it is important to define this common defect and institute appropriate antithrombotic therapy for appropriate time periods.

KW - Anticardiolipin antibody

KW - Lupus anticoagulant

KW - Miscarriage

KW - Premature stroke

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0033381411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033381411&partnerID=8YFLogxK

M3 - Article

C2 - 10629391

AN - SCOPUS:0033381411

VL - 29

SP - 100

EP - 110

JO - Haemostasis

JF - Haemostasis

SN - 0301-0147

IS - 2-3

ER -